• 1
    Bray F, Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 14: 113242.
  • 2
    Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6: 5523.
  • 3
    Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3, Art No: CD000402.
  • 4
    Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005; 366: 40921.
  • 5
    Wells M, Sturdee DW, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, Vessey MP, Bragg AJ. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002; 325: 23943.
  • 6
    Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 2005; 365: 1526.
  • 7
    Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc 2006; 3: 11525.
  • 8
    Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women's health initiative randomized trial. JAMA 2003; 290: 173948.
  • 9
    Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C, Weiss NS. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007; 197: 139.e1e7.
  • 10
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 11317.
  • 11
    Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian long cycle study group. Maturitas 1999; 32: 16170.
  • 12
    Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Causes Control 2001; 12: 11115.
  • 13
    Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006; 98: 28896.
  • 14
    Langer RD, Landgren BM, Rymer J, Helmond FA. Effects of tibolone and continuous combined conjugated equine estragen/medroxy progestesrone acetate on the endomterium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006; 195: 13207.
  • 15
    Archer DF, Hendrix S, Ferentczy A, Gallagher JC, Rymer J, Skouby SO, den Hollander W, Stathopoulos V, Helmond FA. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007; 4: 86678.
  • 16
    Varma R, Sinha D, Gupta J. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. Eur J Obstet Gyncol Reprod Biol 2006; 125: 928.
  • 17
    Sturdee DW. Endometrial safety and bleeding with HRT: whats's new? Climacteric 2007; 10: 6670.
  • 18
    Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Nationwide study on endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009; 114: 11971204.
  • 19
    Keskimaki I, Aro S, Teperi J. Regional variation in surgical procedure rates in Finland. Scand J Soc Med 1994; 22: 1328.
  • 20
    Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010: 126; 4839.
  • 21
    Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 6476.
  • 22
    Chubak J, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev 2004; 13: 12961301.
  • 23
    Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer 2002; 98: 91215.
  • 24
    Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491505.
  • 25
    Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999; 32: 1415.
  • 26
    Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953–2010. Br J Cancer 2004; 90: 17569.
  • 27
    Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, Hill DA, Weiss NS. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 2006; 164: 5662.
  • 28
    Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 45861.
  • 29
    Lacey JV, Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005; 14: 172431.
  • 30
    Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 111016.
  • 31
    Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004; 191: 114651.
  • 32
    Lacey JV, Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA. Endometrial cancer and menopausal hormone therapy in the national institutes of health-AARP diet and health study cohort. Cancer 2007; 109: 130311.
  • 33
    van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56: 23148.
  • 34
    Stanczyk FZ. All progestins are not created equal. Steroids 2003; 68: 87990.
  • 35
    Guttinger A, Critchley HOD. Endometrial effects of intrauterine levonorgestrel. Contraception 2007: 75: 938.
  • 36
    Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five years experience. Fertil Steril 1999; 72: 1613.
  • 37
    Varila E, Wahlström T, Rauramo I. A 5 years follow up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 96973.
  • 38
    Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S Seifert W, Verweij PJ, Cummings SR. Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol 2008; 112: 6539.